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clinical results in tumor-bearing animals 
 
Abstract 
 
Hyperthermia (HT) as an adjuvant to radiation therapy (RT) is a multimodality treatment 
method to enhance therapeutic efficacy in different tumors. High demands are placed on the 
hardware and treatment planning software to guarantee adequately planned and applied HT 
treatments. The aim of this prospective study was to determine the effectiveness and safety of 
the novel HT system in tumor-bearing dogs and cats in terms of local response and toxicity as 
well as to compare planned with actual achieved data during heating. A novel applicator with 
a flexible number of elements and integrated closed-loop temperature feedback control 
system, and a tool for patient-specific treatment planning were used in a combined 
thermoradiotherapy protocol. Good agreement between predictions from planning and clinical 
outcome was found in 7 of 8 cases. Effective hyperthermia treatments were planned and 
verified with the novel system and provided improved quality of life in all but one patient. 
This individualized treatment planning and controlled heat exposure allows adaptive, flexible 
and safe HT treatments in palliatively treated animal patients. 
 
Keywords: hyperthermia, adaptive treatment planning, radiation, dogs, cats 
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Zusammenfassung 
 
Hyperthermie in Kombination mit der Strahlentherapie gilt als eine multimodale 
Behandlungsmethode um den therapeutischen Effekt in verschiedenen Tumorarten zu 
steigern. Hohe Anforderungen werden an die Hardware und Behandlungssoftware gestellt, 
um eine adäquat geplante- und applizierte Hyperthermiebehandlung zu gewährleisten. Die 
Ziele dieser prospektiven Studie beinhalten die Effektivität und Sicherheit des neuen 
Hyperthermiesystems in acht caninen und felinen Tumorpatienten hinsichtlich der lokalen 
Therapieansprache und Toxizität zu testen und die geplanten mit den applizierten 
Behandlungsdaten während des Heizvorganges zu vergleichen. Ein neuer Hyperthermie 
Applikator, welcher aus einer flexiblen Anzahl von Elementen besteht und ein integriertes 
thermisches Feedback-system enthält, sowie eine patienten-spezifische Planungssoftware 
wurden in einem kombinierten Thermoradiotherapie Protokoll verwendet. Gute 
Übereinstimmungen zwischen den Vorhersagen der Therapieplanung mit den klinischen 
Ergebnissen wurden in 7 von 8 Fällen gefunden. Effektive Hyperthermiebehandlungen 
konnten mit dem neuen System geplant und angewandt werden und führten zu einer 
verbesserten Lebensqualität in allen bis auf einen Patienten. Die Kombination aus der 
individuellen Behandlungsplanung und der kontrollierten Wärmeübertragung liefert eine 
adaptive, flexible und sichere Hyperthermiebehandlung von palliativ behandelten 
Tierpatienten.  
 
Schlüsselwörter: Hyperthermie, adaptive Therapieplanung, Strahlentherapie, Hunde, Katzen 
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Introduction  
Hyperthermia (HT) in conjunction with radiation therapy (RT) has long been employed as a method to 
increase therapeutic efficacy in certain tumors.1-6 The uniform application of heat to a localized tumor 
is difficult to achieve due to the inhomogeneous anatomy with large dielectric contrasts, intra-tumoral 
tissue heterogeneity and physiologic counter-regulation, making the prediction or measurement of the 
temperature distribution demanding.7-9 The application of HT places high demands on both the 
applicator hardware and treatment planning to guarantee accurate steering and an effective, safe 
therapy. Similar to RT systems, HT applicator systems should not only include the hardware 
component but also integrate a software component. i.e., suitable planning and control tools which 
allow predictive planning and steering of thermal dose administration. Accurate exposure control to 
prevent under-exposed target regions and unwanted hotspots in healthy tissue require a precisely 
controlled applicator system (amplitude and phase), precise spatial positioning of the applicators with 
respect to the patient body, high-resolution electromagnetic (EM) and thermal simulations considering 
at least the local anatomy and adequate tissue models (dielectric, thermal, perfusion).10-12 Either a 
reliable prediction or a closed-loop system with thermometry-based feedback is needed to ensure a 
good correlation between planned (applied) dose and the effectively deposited heat in specific tissues 
over the time of treatment.  
Over the last decade, progress has been made in terms of improved treatment accuracy and 
treatment planning guidance. Paulides et al.13-15 showed that pre-treatment planning simulations and 
improvements in hardware elements (water bolus shape stability) as well as accurate patient 
positioning optimize the treatment quality in human head and neck cancer patients. Their approach 
involved 3D patient-specific EM and thermal simulations, which improve focused deposition of 
energy and enable conformal, reproducible and adaptive HT applications.  
Thermal dose quantities are intended to enable a comparison of different treatments regarding 
biological effectiveness. This is not possible by a single temperature figure; instead, temporal changes 
and spatial temperature inhomogeneities should be taken into account.16  
In the present prospective pilot study, we treated tumor-bearing companion animals in order to 
test the clinical use of a new multi-modular radio-frequency (RF) applicator system and treatment 
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planning tool for HT. By using EM, thermal, and induced effect simulations, the individual placement 
of applicators as well as their main parameters were optimized and temperature predictions were 
made. During treatment, temperature probes - implanted prior to the first treatment - supervised safe 
delivery, validated temperature predictions and allowed adaptation of energy delivery. For evaluating 
treatment intensity two different approaches, the CEM isodose concept and a transient thermal dose 
equivalent (TTDE) were used.17 
The primary goal of our study was to test the applicability of the novel HT hard- and software 
components in clinical tumor-bearing dogs and cats, and to compare planned with actual achieved data 
during heating. As secondary endpoints, response to treatment was described with respect to observed 
toxicity and local tumor response in the treated animal patients. 
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Material and methods  
HT treatment was performed using a novel applicator prototype (developed by the IT’IS Foundation, 
Zurich, Switzerland) with the possibility of grouping multiple elements to form an array with a 
flexible number and position of the elements, and an integrated closed-loop radiated electromagnetic 
field (EMF) feedback control system. Thermal delivery was prospectively planned with treatment-
planning tool that was developed based on the computational life sciences platform Sim4Life (ZMT 
Zurich MedTech, Zurich, Switzerland). The treatment-planning tool was empowered to segment 
individual animal patients with iSEG (ZMT Zurich MedTech, Zurich, Switzerland), to semi-
automatically optimize the placement of the applicator system, to determine personalized steering 
parameters using a dedicated field optimizer, and to perform analysis and visualization functionality. 
For the current investigation, feline and canine tumor animal patients with various types of inoperable 
cancers were included. In this experimental clinical setting, we used multiple temperature probes in 
order to validate the predicted intra-tumoral and superficial temperatures achieved during treatment. 
The measurement data obtained was then used to ensure that the applied treatment corresponds the 
predictions made during planning and allowed real-time adjustment in order to provide effective and 
safe heating.  
 
Animal patient criteria 
Dogs and cats presented to the Division of Radiation Oncology, Vetsuisse Faculty (University of 
Zurich, Switzerland) for treatment of inoperable bulky malignant tumors between July 2015 and 
August 2016 were included into the study. No preselection with regard to applicability of 
hyperthermia, e.g., based on modeling of the expected heating quality, was performed, resulting in an 
extremely heterogeneous group of animals with regard to tumor type, location, and heatability. Each 
animal had a clinical work up (tumor staging) as appropriate to the type of presenting disease. Written 
owner’s consent was obtained for invasive sampling in this study. The work was carried out in strict 
accordance with the recommendations and the protocol approved by the Animal Ethics Council of the 
Canton of Zurich, Switzerland (Permit Numbers: 172/13 and ZH065/16). All treatment and invasive 
sampling procedures were performed under anesthesia with appropriate analgesia, and all efforts 
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were made to ensure minimized suffering. 
 
Hyperthermia and radiotherapy treatment planning 
A treatment planning computed tomography (CT) was acquired in an individually prepared 
immobilization device: animals were positioned in a vacuum cushion (BlueBag BodyFix, Elekta AB, 
Stockholm, Sweden) and a custom-made bite block was used, if required18. Immobilization also served 
the purpose of achieving reproducible positioning and to align planning and treatment. A non-contrast 
and contrast-enhanced study was performed to visualize the tumor. Subsequently, temperature 
transponder seeds (IPTT-300, Bio Medic Data Systems, Inc., Seaford, USA) were implanted in a 
minimally invasive manner in viable tumor areas, avoiding cystic or necrotic regions, which are likely 
to result in sensor migration. After implantation, an additional CT study was performed to confirm the 
transponder location. Both, the initial CT (without transponders) and the post-injection CT (with 
transponders) were later used for segmentation. 
RT treatment planning was performed in all cases by a board-certified radiation oncologist 
(CRB) on the basis of 3D CT data using the Eclipse External Beam Planning system version 10.0 
(Varian Oncology Systems, Palo Alto, USA). Tumor related volumes were contoured as follows: the 
gross tumor volume (GTV) was delineated using co-registered contrast-enhanced CT sequences; the 
clinical target volume (CTV), accounting for subclinical microscopic disease extension, was defined 
according to the radiation oncologist’s choice for the respective disease; and, based on tumor location,  
the CTV-PTV margin extension was a three-dimensional extension by 2-5 mm to define the planning 
target volume (PTV), accounting for systematic and random uncertainties. Organs at risk were 
specified as required. 
For HT treatment planning, the CT images and the previously defined tumor (GTV) and 
organs at risk related volumes from the RT treatment planning (RTstruct DICOM images) were 
imported into iSEG. This segmentation toolbox features a set of flexible (semi-) automatic 
segmentation methods enabling to generate a detailed 3D-anatomical model distinguishing the large 
number of tissues required for HT treatment planning.19 Basic tissue types were identified based on 
anatomical criteria and Hounsfield units obtained from the non-contrast and contrast-enhanced 
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treatment planning CT. Additional segmentation functionality was used to semi-manually delineate 
relevant organs or organs at risk (e.g. spinal cord, bone marrow, liver, kidney) that were not clearly 
distinguishable by their contrast, however vary in their physical, dielectric and thermal properties. The 
segmented tissues were later assigned physical (i.e., mass density), dielectric (i.e. electric conductivity 
and permittivity), and thermal (i.e. thermal conductivity, specific heat capacity, heat generation rate, 
and temperature dependent perfusion) tissue properties.20 In order to know their position, the 
temperature sensors (see below) were also included in the segmentation, allowing prediction of 
temperature recordings during treatment. Subsequently, the treatment-planning enhanced Sim4Life 
platform was used for surface generation and visualization of the segmented anatomical model to then 
plan optimized therapy administration. EM and thermal simulations were performed to identify the 
optimal number of applicators, their placement and polarization, the water-bolus/boluses temperature, 
as well as the applicator parameters (i.e. phase and amplitude of delivered fields). Geometrical 
placement of the applicator was interactively defined, with the possibility of automatically generating 
3D printable fixation mask. Alternatively, simple dielectric supports could also be generated to fix the 
applicators in their final position. EM simulations were performed using a finite-difference time-
domain (FDTD) solver to compute the full-wave solution of Maxwell’s equations. A modified version 
of the Pennes Bioheat Equation (PBE) with advanced perfusion and thermoregulation modeling 
accounting for vasodilation was used for the temperature simulations. The temperature dependency of 
the perfusion in the tumor,21 muscle, fat and skin22, 23 was modeled and considered in all the 
simulations. Effect-related thermal dose quantities such as isopercentiles of temperature or CEM43 
(cumulative equivalent minutes at 43°C)16 were computed, analyzed, and displayed providing, e.g., a 
visualization of the effective treatment volume with an overlay of the efficacy/risk maps, or systematic 
assessment of tumor coverage and sensitive tissue exposure through cumulative histograms.  
 
Applicator 
The newly designed applicator prototype (Figure 1) consists of different elements, including a cavity-
backed slot antenna,24 operating in the industrial, scientific, and medical band at 433.92 MHz, 
positioned around or near the region to be treated. The design of the applicator offers full flexibility 
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with respect to the location at which the applicator can be placed, the orientation, and the number of 
applicators to be used for the treatment.25 Different paradigms can be used depending on tumor 
location, namely, coherent (phased-array) or incoherent (specific absorption rate (SAR)) combining 
techniques, to raise the temperature of the tumor by focusing energy into it. Cavity-backed slot 
antennas are chosen for this application because of their wide bandwidth and hence tolerance to 
changes in environment (‘loading conditions’), such as proximity to the patient, tissue parameters, and 
morphology. A technique based on sensing the radiofrequency (RF) current flowing in each of the 
applicator elements is employed to determine the amplitude and phase of the total field radiated due to 
both direct and coupled excitations of the elements, and hence provides a measure in terms of SAR of 
the power absorbed by the tissues. The measurement is performed by an integrated data acquisition 
system. The applicator elements have an overall external area of 75 mm x 75 mm. The effective heat 
transfer coefficient of the water boluses was determined experimentally and applied subsequently in 
the thermal simulations as a convective boundary condition. 
 
Figure 1. Picture showing the 3D view window of the treatment-planning tool with the optimized 
placement of one of the novel applicator modules on the tumor of a cat (animal 6). In this case, the 
vaccine-associated sarcoma is located on the right caudodorsal abdominal wall. (only the caudal 
abdomen and pelvic region relevant for reliable modeling is segmented) 
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Hyperthermia treatment 
HT was performed once per week for three sessions in total, in each case prior to RT. All animal 
patients were under general anesthesia and positioned in the individually shaped vacuum cushion and, 
if treated in the head area, a bite block, providing rigid immobilization and reproducibility of treatment 
position, compared to the planning position. An array of between one and six RF-applicators with 
individual water-filled boluses can be applied around a localized tumor, according to the individual 
treatment plan. In order to avoid the gross mismatch that can occur when an applicator operates with 
air between the bolus and patient, fur over the treated region was clipped and additional absorbing 
material (saline-solution filled bags) was placed around the tumor, if required, to fill air voids present 
due to the shape of the anatomy. If the skin of the tumor was ulcerated, the treated region was covered 
with cling film to avoid contamination. 
Effective heating time was 45 minutes, measured from the time when the first intra-tumoral 
temperature sensor reached ≥41°C, or after 15 minutes of heating-up time had elapsed. In the clinical 
setting, the target tumor temperature was between 41°C and 44°C throughout treatment. Superficial 
skin temperatures were supposed to remain below 42°C. Intra-tumoral temperature was monitored 
with the implanted temperature sensors. Depending on tumor size, two to three sensors were placed in 
the tumor under CT-guidance, subsequently remaining at the implanted site. The transponders were 
placed in tumor regions with the greatest possible distance to each other, to enable optimal 
temperature measurement coverage and readability. Temperatures were evaluated every 5 min with a 
handheld device (DAS-7009 IPTT, Bio Medic Data Systems, Inc., Seaford, USA). For each reading, 
the applicators and boluses had to be removed from the animal. Surface temperatures were 
continuously monitored with a non-invasive T1V3 temperature probe connected to the EASY4 data 
acquisition system (Schmid & Partner Engineering, AG, Zurich, Switzerland), which was placed 
between the water bolus and the skin.  
To quantify the treatment intensity of applied heat, thermal dosimetry was used, meaning that 
the temperature as function of time was translated into a biological effect. It is important to note that 
thermometry alone is not sufficient to achieve this; the temperatures acquired with thermometry need 
to be transformed into thermal doses. Thermal dose was calculated for each temperature sensor and 
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was converted to an equivalent exposure time in minutes at a reference temperature of 43°C, using the 
following formula from Sapareto and Dewey:16 
CEM43 =  R (43-T) t (min) 
where t was 5 min (the time between readouts of the implanted sensors), T is the applied temperature 
of the target tissue and R= 0.25 when T ≤43°C and R = 0.5 when T >43°C. 
Since a physiological thermal dose concept is missing up to now, an alternative approach for TTDE 
was investigated in addition to the CEM43 dose. It is based on a physiologically motivated model,17 in 
which the total amount of repair protein is divided into two parts: The amount of nonfunctional repair 
protein Λand the amount of functional repair protein Υ = 1 −Λ . Λ is a dynamic quantity that rises 
during heating and decays subsequently due to repair processes. The change in functional repair 
protein amount then consists of the amount of non-functional repair protein that becomes functional 
minus the amount of functional repair protein that becomes non-functional: 
dΛ(𝑡)
d𝑡
= 𝑘1Υ(𝑡) −  𝑘2Λ(𝑡)  
First order kinetics are assumed; the coefficient 𝑘1is given by the Arrhenius equation 
𝑘1 =  𝜅𝑒
−𝐸𝑎 (𝑅𝑇)⁄  with 𝜅 =  𝑎 ∙ 𝑒𝐸𝑎 (𝑅𝑇𝑟𝑒𝑓)⁄  
where 𝑅 =  8. 314 J mol-1  K-1, 𝑇 is the temperature in [K] and 𝑡 is the time. A constant parameter 
𝑘2 = 2.76 h
-1 is assumed. The pre-exponential factor of the Arrhenius equation 𝜅 consists of 𝑎 =
0.56 ∙ 10−3 h-1 and a factor introduced for numerical reasons with 𝑇𝑟𝑒𝑓 = 310.15 K. The activation 
energy is set to 𝐸𝑎 = 1528 kJ/mol. Those values were found by fitting the data presented by Sapareto 
and Dewy,16 and were published by Scheidegger et al.17 Note how this model does not incorporate the 
change of activation energy when the temperature exceeds 43°C, unlike the behavior postulated by the 
CEM43 model. The initial condition is derived from the steady-state at standard body temperature, is 
Λ(0) = 𝑘1/(𝑘1 + 𝑘2) ≈ 0.  
Λ is evaluated at two points in time for two thermal dose candidates: the first one is the maximum 
amount of nonfunctional repair protein during the procedure, Λ𝑚𝑎𝑥. The second one, Λ𝑔𝑎𝑝, is the 
amount of nonfunctional repair protein at the time of irradiation 𝑡𝑅𝑇, taking into account the time-gap 
between HT and RT.  
11 
Radiation therapy 
RT was applied after HT while trying to keep the time gap between the two treatment modalities as 
short as possible. Time from shutting-off the RF-power to applying the first radiation beam was 
recorded for each animal and treatment. RT was delivered with a 6 megavolt (MV) linear accelerator 
(Clinac iX, Varian, Palo Alto, USA) using photons and a 3-dimensional conformal technique. The 
recommendations for specifying dose and treatment volumes as proposed for veterinary medicine were 
adhered to.26-28 The protocols used correspond to commonly used protocols for palliative treatment in 
animals. For sarcoma, a total of 30 Gy delivered in five fractions of 6 Gy applied twice per week (as 
shown in Figure 2), resulting in an overall treatment time of 2.5 weeks.29 For oral melanoma, a total of 
32 Gy was prescribed and delivered in 4 x 8 Gy weekly.30, 31 
 
Figure 2. Graphical illustration of a 5 x 6 Gy radiation therapy protocol in combination with 
hyperthermia used for the treatment of soft tissue sarcoma. 
 
Response evaluation and follow-up 
After treatment, animals were re-evaluated after three weeks, two, three, four and six months and then 
at three-month intervals. Follow-up information included physical examination with measurement of 
the tumor and individualized imaging based on tumor type, stage and clinical signs. A modified 
Karnofsky´s performance score32 was performed before treatment initiation, during HT treatments and 
regular re-checks. Pre- and post-treatment tumor volumes were extracted with the contouring tool of 
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the Eclipse External Beam Planning system version 10.0 (Varian Oncology Systems, Palo Alto, USA) 
or by the manual calculation of an ellipsoid (V = π / 6 x (L x W x H)) using caliper and / or CT-
measurements. On the last treatment day as well as no later than six months after the end of the 
treatment, a CT of the tumor region was performed and was repeated every six months thereafter. 
Tumor response was evaluated, based on size measurements, using the response evaluation criteria in 
solid tumors (RECIST) for dogs.33  
At time of progression, animal patients were allowed to receive additional treatment (e.g. 
metronomic chemotherapy or surgical debulking). Radiation-induced toxicity was scored using the 
Veterinary Radiation Therapy Oncology Group (VRTOG) scheme each time RT was applied, and at 
regular re-checks.34 Hyperthermia-specific side effects were graded according to the Common 
Toxicity Criteria Adverse Events (CTCAE) v4.0335 and Quality Management in Hyperthermia 
(QMHT)35 on each treatment day and on all follow-up examinations.  
 
Statistical analysis 
Data was compiled in Excel (Microsoft, Redmond, USA). 
Descriptive statistics are reported on the following variables: (1) pre-treatment longest tumor diameter, 
(2) maximum reduction of the longest diameter after treatment, (3) reduction in tumor volume, (4) 
time to greatest response and (5) median skin temperature during treatment, as well as on the three 
thermal dose candidates (6) C𝐸𝑀43, (7)Λ𝑚𝑎𝑥, and (8) Λ𝑔𝑎𝑝. 
Progression free interval (PFI) was defined as the interval between the first hyperthermia treatment to 
measurable local or distant tumor progression. Overall survival (OS) was defined as the time between 
the first hyperthermia treatment and death from any cause. Follow-up time was defined as time 
between the first hyperthermia treatment and the last re-check or death. 
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Results  
Animal patient and tumor characteristics 
Eight client-owned companion animals were included into a combined thermoradiotherapy protocol 
receiving in total three sessions of HT as an additive to hypofractionated RT.  
Animal and tumor characteristics are summarized in Table 1. Two animals were treated with a 
deviating RT protocol: in one dog (animal 1) a smaller fraction size was used with the initial plan to 
downstage the tumor and render it amenable to surgery. A total dose of 36 Gy, applied in 12 x 3 Gy 
(daily fractions) was given. Animal 3 had been pretreated 15 months earlier with a 5 x 6 Gy palliative 
protocol and for the re-treatment a more conservative approach of 3 x 5 Gy, applied concurrently with 
the three weekly HT treatments was used.  
 
Hyperthermia treatment parameters  
Results obtained from treatment planning provided guidance for setting up the starting parameters 
during the therapy, namely the applicators position and polarization, the power (amplitude and phase) 
of the RF signal for each applicator, and the temperature of the water flowing within the bolus. 
Because of the intrinsic uncertainties and approximations in modeling the treatment (heterogeneous 
distribution of blood flow in actual GTV, accuracy of anatomical model, uncertainties about EM and 
thermal properties of the tumor, transponder migration from injection time to each session, applicator 
positioning), real time power strength adjustments based on the measured temperatures of the 
transponders (see also Figure 3) and the instantaneous temperature readouts of the skin were 
performed: in total, 490 intra-tumoral temperature readouts were conducted during the effective 
heating period in all animals, 320 (65 %) of them were within the range of 41 – 44°C. The power had 
to be adjusted with a mean of 4.25 times ( 2.2 times) during the treatments. Skin temperature was 
measured continuously whenever possible (available in 15 out of 24 treatments) to avoid excessive 
heating (>42°C). In six treatments (animals 6, 7, 8) skin temperature was elevated above this target for 
between 4.47 and 49.67 minutes (median 11.0 min) to allow therapeutic tumor temperatures. 
Simulated times to reach therapeutic temperatures were always shorter than those required in reality as 
the need to stop the treatment to read the implanted temperature sensors lead to a drop in tumor 
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temperatures. Hence, the overall treatment time (heating up + effective heating time + temperature 
readouts) took in 17 (71 %) out of 24 cases more than the desired 60 min. The mean time to reach 
intra-tumoral temperatures ≥41°C in at least one temperature sensor was 15 min ( 8 min) and in one 
case (animal 7) the target temperature was not achieved during the entire treatment. In cases where the 
target therapeutic temperatures were not reached within the intended heating-up time (n = 5), 
therapeutic time was still initiated to avoid prolonging anesthesia of the animals. Mean heating-up 
time in all treatments was 13.1 min ( 5.4 min) and the mean effective heating time (power turn-offs 
included) was 52.4 min ( 7.0 min). Mean time between HT and RT treatment was 21.6 min ( 8.4 
min), deviations occurred due to positioning verifications of the animals before RT treatment.  
 
Figure 3. Comparison between planned and applied treatment for one treatment of animal 6. (a) 
Simulated and measured temperatures inside the tumor as a function of time: (1) the original 
optimized treatment plan using a constant power strength, (2) the actual temperatures obtained from 
the transponders every 5 min, including the temperature drop at the end of the therapy for one of the 
transponders, and (3) simulation after therapy application, considering the variation of applied power 
during the therapy and the exact time slots when the power was turned off and the water bolus was 
removed (i.e. the periods in which the temperature from the sensors was acquired). (b) Power applied 
to the applicator as a function of time according to the original treatment plan and the actually applied, 
dynamically adjusted (based on temperature sensors) power during the session. 
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Expected and measured temperatures, as well as the computed and applied power in the 
applicator as a function of time for one of the treatments of animal 6, are displayed in Figure 3. In the 
transient region (i.e., the region in which the temperature changes with time before reaching a steady 
state), the measured temperatures were approximately 2°C below the predicted value, even 
considering the actual power and bolus absence. Besides the EM and thermal parameter uncertainties, 
the deviations can be attributed to uncertainty about dielectric, thermal, and perfusion properties of the 
various tissues, and especially the heterogeneous tumor region. Additionally, literature data on the 
temperature dependence of the tumor perfusion is sparse and important variability exists between 
tumor types, such that the applied perfusion model also contributes to the uncertainty. Nevertheless, 
the main impact on the temperature response was a prolongation of the transient regime. In the steady 
state, the deviations between the measured values and both, the original plan and the realistic 
simulation, were considerably decreased. The temperatures acquired by the transponders during each 
treatment give some indication of the uniformity of heating. Table 2 shows the minimum and 
maximum intra-tumoral temperatures measured by the transponders during the effective heating time 
for each therapy session. This range indicates how uniformly the tumor was heated over time, after 
reaching the temperature criteria for hyperthermia. The same table summarizes the main parameters 
for all animals at each therapy session (number of applicators, initial power amplitude and water bolus 
temperature). A useful metric for evaluating the quality of a planned treatment is the volume-
normalized temperature histogram. The histogram allows estimation of the temperature uniformity 
inside the tumor, but also indicates for this study that sensitive tissues (e.g. the spinal cord) were 
within a safe temperature range. Figure 4 shows the corresponding temperature histograms for the 
GTV and the spinal cord, respectively, for animal 6. As illustrated, 74 % of the tumor volume is 
expected to reach at least 41°C, 44.6°C being the maximum temperature. On the other hand, the spinal 
cord is expected to always remain below 39.3°C.  
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Figure 4. Temperature histograms for (a) the GTV and (b) the spinal cord in animal 6. In the case of 
the tumor, 74% of its volume is expected to reach at least 41°C, 44.6°C being the maximum 
temperature. The spinal cord temperature is expected to always remain below 39.3°C. 
 
Typical metrics for assessing the homogeneity of heating inside the tumor are T90 and T10, 
defined as the temperature reached by at least 90 % and 10 % of the tumor volume, respectively. The 
cumulative histogram for the GTV is used in the treatment planning to calculate the T90 and T10 
factors, as summarized in Table 2 for all the animals. The difference T = T10 – T90 gives an 
indication of the uniformity of heating inside the tumor; a smaller T indicates a more uniform 
heating. It should, however, be noted that uniform heating alone does not guarantee that the tumor 
reaches therapeutic temperatures. A valuable predictor of treatment efficacy is provided by 
ascertaining a T90 close to or above 41°C. This last criterion was fulfilled in three animals (1, 4 and 6) 
suggesting the most effective hyperthermia treatment in these animals, whereas for animal 3 T90 was 
smaller (38.9°C), resulting in moderate effectiveness. The treatments for animals 2, 7 and 8 were 
difficult to plan due to the large tumor burden (194.0 cm3, 912.4 cm3, and 230.4 cm3, respectively). 
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Corresponding values of T90 and T indicate, only partial tumor heating to 41oC and higher and 
rather inhomogeneous tumor temperatures. Despite the inhomogeneity of the treated animal group, a 
correlation is apparent when comparing clinical responses with the predictions from planning. With 
the aim of having an indicative metric of the effectiveness of the treatment plans, the ratio of these 
volumes has been correlated with T90 from Table 2. Figure 5 shows the correlation between T90 
inside the tumor from planning and the percentage of tumor volume which remained after treatment. 
The graph includes the original volume for each animal patient. Improved clinical responses are 
expected for those animals in which T90 is closer to 41oC (Table 2). In seven out of eight animals, a 
correlation between predictions from planning and clinical outcome was found. One exception is 
animal 5, the only treated patient with an oral malignant melanoma. This correlation does not 
constitute proof of a causal relationship between increased T90 dose and tumor shrinkage, as the 
tumor volume also correlates with both T90 and tumor shrinkage and thus constitutes a confounding 
variable. The increased tumor shrinkage could thus be related to increased heatability of small tumors, 
or to increased responsiveness, or to unknown additional factors. Due to the small and heterogeneous 
patient population, statistical separation of influence factors is not feasible. 
 
Figure 5. Remaining tumor volume after treatment versus T90 from GTV histograms for each animal 
patient.  
 
Response evaluation 
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Median follow-up time was 283 days (range 62 – 558 days). Response was noted in each animal; time 
to greatest response varied from 19 to 153 days with a mean of 77 days (47.2 days). Four animals 
(animal 1, 4, 5, 6) showed PR with a maximum reduction in the longest diameter ranging from 48.7 to 
90.7 % with a mean of 66.7 % (17.6 %). The remaining four animals showed SD (animal 2, 3, 7, 8); 
all of them had a maximum reduction in the longest diameter ranging from 4.5 to 24.2 % with a mean 
of 15.7 % (8.2 %). When assessed volumetrically, a reduction in tumor volume was achieved in 
every case with a mean of 62.9 % (36.6 %) based on caliper measurements. Tumor volumes and 
longest diameters are listed in Table 1. A modified Karnofsky´s performance grade of 0 was seen in 
one patient (12.5 %), grade 1 in six patients (75 %) and grade 2 in one patient (12.5 %) before therapy. 
During HT treatments five animals experienced five episodes of altered Karnofsky´s performance 
score. While four patients improved, one patient’s score worsened compared to pre-treatment. During 
follow-up, five animals showed improved grades, one patient was recorded to worsen and two patients 
experienced no change towards baseline.  
 Of the six deceased animals, four were euthanized due to tumor-related progression causing 
ulceration (animal 1), bleeding (animal 2) and pain/ severe lameness (animal 8). Animal 5 showed a 
paraparesis of the left hind limb; further diagnostics were not performed, however metastasis of the 
oral melanoma could not be excluded. The other two animals (animal 3, 6) died most likely of non-
tumor related causes, however necropsy was not available in these animals. Two animals were alive at 
the end of the study period.  
In four animals additional therapy was initiated at disease progression. Metronomic 
chemotherapy, consisting of oral administration of cyclophosphamide (15 mg/m2 once daily), 
thalidomide (2-4 mg/kg once daily) and a non-steroidal anti-inflammatory drug (piroxicam or 
firocoxib using the recommended standard dose)29 was initiated. In animal 5 metronomic 
chemotherapy was discontinued after 151 days due to massive disease progression and oral 
Temozolomide was administered once daily for five consecutive days at a dosage of 60 mg/m2 every 
28 days.30 The dog received two such cycles until treatment was discontinued and the dog euthanized 
due to disease progression. (Table 1) 
Side effects (toxicity) 
19 
Acute thermal side effects were seen in one animal (animal 1). The dog was in slight pain (increase in 
heart-, and respiratory rate during anesthesia, degree I) and developed a mild erythema in the area of 
the treated skin (degree II). The treatment was continued with a power reduction and symptoms 
resolved spontaneously after the treatment (Table 1). No subacute or late thermal side effects were 
observed in any of the animals. Radiation toxicity was mild and not more severe than previously 
described for the same radiation protocol:29 grade 1 acute toxicity of the skin was seen in seven 
animals (alopecia/epilation, erythema or dry desquamation) and/or in the mucous membranes 
(injection of the mucous membranes without mucositis) and grade 2 acute toxicity was present in the 
skin of one animal (patchy moist desquamation, without edema). Mild late side effects were seen in 
five animals with grade 1 toxicity including alopecia or leukotrichia. Transponder-related side effects 
were seen in two cases. In one case (animal 3), one of two transponders was expelled nine days after 
the placement causing a non-healing wound. No hyperthermia treatment was applied up to this time. 
In the second case (animal 7), three transponders were placed intra-tumorally, all of them stayed at the 
implanted site, however at one access/ incision site the skin did not heal, causing ulceration of the 
tumor. Both animals received the combined treatment as planned, but nonetheless needed surgical 
management afterwards. This included a debridement in the first case and a debulking of the tumor in 
the second case. 
 
Thermal dose calculations 
Of the 24 performed HT sessions, transponder readings from different locations could be evaluated 
during each treatment: temperature data was available (1) from three transponders for five treatments, 
(2) from two transponders for 14 treatments, and (3) from a single transponder for five treatments. The 
dose concepts 𝐶𝐸𝑀43 (equivalent heating duration in minutes at 43°C), Λ𝑚𝑎𝑥 (largest amount of 
damaged repair protein) and Λ𝑔𝑎𝑝 (amount of damaged repair protein at the time of irradiation) were 
calculated for those 48 temperature data time series. Mean values (±SD) of 𝐶𝐸𝑀43̅̅ ̅̅ ̅̅ ̅̅ ̅̅  = 28.74 (±33.89), 
Λ𝑚𝑎𝑥̅̅ ̅̅ ̅̅ ̅̅  = 0.41 (±0.32) and Λ𝑔𝑎𝑝̅̅ ̅̅ ̅̅ ̅ = 0.13 (±0.10) were found. Figure 6 shows scatter plots of Λ𝑚𝑎𝑥 vs. 
𝐶𝐸𝑀43 and  Λ𝑔𝑎𝑝 vs. 𝐶𝐸𝑀43, respectively. 
The Spearman rank correlation for Λ𝑚𝑎𝑥 vs. CEM43 is ρ = 0.98 and for Λ𝑔𝑎𝑝 vs. CEM43 is ρ = 0.90. 
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Figure 6. Scatter plot of Λmax vs. CEM43 (left) and  Λgap vs. CEM43 (right). Values with 
temperatures above 43°C are marked with a triangle. Each animal patient is assigned a distinct color. 
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Discussion  
Prior work has proven the effectiveness of HT in combination with RT and justifies its use as an 
additional treatment modality in the battle against cancer.5, 36 However, continued investigation and 
improvements regarding hardware and treatment planning software, as well as thermometry are 
mandatory to ascertain treatment quality, optimize outcome, and increase acceptance of HT as a more 
routine treatment option. In addition, anatomical tissue inhomogeneity with highly relevant dielectric 
contrast and variable tissue perfusion, intra-tumoral tissue heterogeneity, and lack of precise knowledge 
about the involved mechanisms (and hence the effect-related dose to be optimized) complicate the 
achievement of an optimal strategy for energy deposition and temperature elevation in the tumorous 
tissue - while avoiding overexposure of sensitive healthy tissue - and increases the demand for a mature 
technology. 
In this study, we describe the application of an adaptive HT treatment system, preliminarily 
tested on a group of canine and feline cancer patients treated with three sessions of HT as an adjuvant 
to standard palliative RT. We further present toxicity profiles and describe clinical response in order to 
test the safety of the new system. Different tumor entities, locations and sizes were included, 
demonstrating the wide and flexible use of the hard- and software components.  
In particular, large, bulky tumors have shown to challenge treatment planning in terms of 
achieving a homogenous temperature distribution. Temperature variations between sessions within the 
same animal and for the same transponders might be due to composition changes of the tumor tissue 
properties during or between treatments caused by altered blood supply and/or tumor shrinkage, as 
well as errors in reproducing the applicator positions exactly. Additionally, migration of the 
transponders inside the tumor between the individual HT sessions may also contribute to temperature 
variations since the actual measurements often do not reflect the initial, planned situation. Power 
adjustments were needed to achieve the aimed intra-tumoral temperatures. Despite these adaptions 
approximately 1/3 of measurements were out of the target range – most of them below 41°C. This fact 
might be explained by the rapidly raising skin temperatures under treatment, leading to a restriction of 
further power elevations in some cases to avoid skin damage. Nevertheless, skin temperature limits 
were temporarily exceeded in a few cases and in two animals almost during the entire treatment; still 
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none of them developed any side effects. All of the affected animals showed less than 41 CEM43°C in 
the skin, which is reported to be the thermal dose threshold for irreversible skin damage.37, 38 The 
maximum CEM43°C reached in the skin of our animals was 30.3 CEM43°C.  
Taking into account the heterogeneity of the treated animals, the chosen criteria for the 
planning-based estimation of treatment effectiveness have demonstrated good agreement with the 
clinical results and could be suitable as treatment optimization goals in future treatment planning. 
Despite the predictions for animal 5 suggesting moderate heating, results showed a reduction in tumor 
volume of nearly 100 %, which is consistent with previous publications of response of canine oral 
melanoma treated with hypofractionated RT. The reported overall response rates to RT for oral 
melanoma are 82 to 94 %39 and may explain the clinical response in this case despite the moderate 
heating provided by HT. Cats 4 and 6, which suffered from vaccine-associated sarcoma (VAS), were 
supposed to have the most effective HT treatment based on the treatment planning (T90 criterion) and 
showed encouraging local responses with tumor volume reductions varying from 89 to 92 %.  
Additionally, animal 4 showed PFI of 13.3 months and was still alive at the end of data analysis. In a 
previous study, cats treated with a coarse fractionation RT protocol of 4 x 8 Gy for macroscopic VAS, 
revealed median PFI of 4 months and OS of 7 months.40 
The thermoradiotherapy protocol used here was well tolerated by the animal patients. Apart 
from a single negligible acute HT toxicity that resolved spontaneously after treatment, no thermal 
damage was seen in any of the animals. Acute radiation side effects were mild and easily manageable 
and evident late radiation side effects, assessed during the follow-up period, were without any clinical 
relevance. Although overall treatment time and therefore time of anesthesia was longer than expected, 
animals were able to cope with prolonged therapy well without notable adverse effects. For low 
thermal doses, both scatter plots in figure 6 show a mostly linear correspondence between the C𝐸𝑀43 
figure and the new thermal dose equivalent candidates Λ𝑚𝑎𝑥 and Λ𝑔𝑎𝑝. For higher thermal doses, 
both Λ figures are driven into saturation since the maximum of 1 (100 % of the repair protein are non-
functional) cannot be exceeded. The spread in the  Λ𝑔𝑎𝑝 plot is larger than in the Λ𝑚𝑎𝑥 since 
additional variation is introduced by the differences in time-gaps. As a consequence, the correlation 
between Λ𝑔𝑎𝑝 and CEM43 is lower than between Λ𝑚𝑎𝑥 and CEM43. No clustering around animals 
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and/or fraction of individual patients was observed, suggesting that the different HT sessions of a 
given animal were quite diverse and that the temperature inside the tumor was inhomogeneous. 
Interestingly, such patterns have also been observed in a study in which humans with bladder cancer 
were treated with the BSD-2000 system.41 Comparing the clinical outcome with the thermal dose 
figures is challenging at this point due to the high variability and the low number of patients. So far, 
no clear trend is visible in this regard, although the reduction in the longest diameter seems to be 
elevated at high CEM43 and Λ𝑚𝑎𝑥 figures. This tendency is not visible in Λ𝑔𝑎𝑝. An aggravating 
factor is that the model uses the same 𝐸𝑎 and 𝜅 regardless of whether the temperature is above or 
below 43°C. The computed Λ figures are therefore not accurate for sessions in which the temperature 
exceeded 43°C.  
One main limitation of the study was related to the thermometry used during treatment. Due to 
the limited range of the reading device, temperature readouts required moving the applicator(s) and 
thus interruptions of the heating period, leading to a temperature drop and an extension of the overall 
treatment time. While the impact on therapeutic temperatures can be minimized by fast measurements, 
the frequency of measurements and the number of measuring points remains limited. Furthermore, the 
manual movement of the applicator and the lack of an individualized applicator holder carries the risk 
of positioning variations with respect to the target volume and thereby potentially altering the energy 
deposition. Despite this, the alterations experienced remained minimal and did not negatively 
influence the heating period. However, novel thermometry approaches should be considered to 
increase the number and rate of temperature measurements while avoiding disruptions of the heating 
process. Although the transponders are equipped with an anti-migration device and were placed in 
viable tumor areas under CT guidance, movement within the tumorous tissue was still evident and 
partly complicated readout and interpretation. One of the implanted transponders was rejected before 
the treatment start. Another animal had to be excluded from the study population, since no intra-
tumoral temperature measurements were available. In a third case all injected transponders stayed at 
the implanted site, however at one access/incision site the skin did not heal, causing ulceration of the 
tumor. Further surgical intervention was needed in two of these cases, which included a debridement 
and debulking of the neoplasia, respectively. In these animals the tumor seemed rather active and 
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inflamed and the skin was fragile due to the increased tension that was created by the tumor burden 
itself and in one case additionally by the pre-treatment with RT. To prevent transponder-related 
adverse events, incision sites must be chosen in healthy skin regions overlying the tumor, however 
uncertain tissue characteristics and individual variations in tumor composition during treatment are 
unpredictable factors for therapy preparations. Additionally, tumor shrinkage during treatment 
suggests a need for re-optimization (currently not performed) of the HT administration to compensate 
for changes observed between HT sessions. The study subjects’ heterogeneity regarding animal 
species, tumor types, sizes, and locations makes direct correlations between individual treatments 
difficult, but gives an indication of the wide applicability of the treatment modality and system. 
Moreover, it should be noted that all presented animals and tumors were treated, without treatment 
planning-based preselection, reflecting expected heatability. 
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Conclusion 
In conclusion, our study shows that the novel HT system provides individually adaptive, flexible and 
safe HT treatments using a patient-specific treatment-planning tool and a closed-loop feedback control 
system to ensure that the applied treatment corresponds to predictions. All but one animals 
experienced improved quality of life in a palliative-intent treatment setting. Response cannot be an 
endpoint due to the limited number of heterogeneous cases, however the study provides a proof of 
principle that effective, homogenous heating can be planned and verified. 
Future work should focus on image-based systems enabling re-planning and adaption of the treatment 
plans shortly before each session based on the current anatomical and physiological conditions to 
consider anatomical changes during therapy. In the future, and considering the lessons learned in the 
treatment of these first animals, computational planning should also be used to select patients and 
decide on the suitability of providing HT treatment.  
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Table 1. Summary of patient data, treatment, toxicity and outcome of all eight animals treated with hyperthermia and radiation therapy 
Animal Breed                
Age 
[years] 
Weight 
[kg] 
Tumor type       
Location 
TNM stage 
Pre-treatment 
TV [cm3]                              
LD [cm]  
RT protocol 
[Gray] 
Post-treatment 
TV [cm3]             
LD [cm]  
Best RECISTa 
response 
RT toxicityb 
[grade] 
HT toxicityc 
[degree] 
PFI 
[days] 
Additional 
treatment 
OS   
[days] 
1 
Irish Red and White 
Setter      
9.9 35.4 
PVWT                                    
Right lateral 
elbow 
T1 N0 M0 
13.9                               
5.8 
12 x 3 
1.0                          
2.2 
PR 
Acute: 1                                                       
Late: 0 
Acute: I-II                              
Subacute: 0                   
Late: 0 
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Retreatment after 
481 days 
558 
2 English Bulldog                    6.0 29.0 
HSA                                          
Left inguinal 
T2 N1 M0 
194                             
10.0 
5 x 6 
 185.2                      
8.3 
SD 
Acute: 1                           
Late: 0 
Acute: 0                               
Subacute: 0                 
Late: 0 
120 
Metronomic 
chemo 
264 
3 Boxer                                 11.4 29.5 
PVWT                       
Right carpus 
T2a N0 M0 
74.2                           
6.6 
3 x 5 
26.2                         
5.0 
SD 
Acute: 1                                            
Late: 1 
Acute: 0                              
Subacute: 0                 
Late: 0 
153 
Debridement 
Metronomic 
chemo 
220 
4 
Domestic short-haired               
cat 
15.6 3.1 
VAS                
Interscapular 
T1 N0 M0 
18.6                          
5.2 
5 x 6 
2.0                           
1.8 
PR 
Acute: 1                                            
Late: 1  
Acute: 0                               
Subacute: 0                 
Late: 0 
400  540* 
5 Rottweiler                                14.8 30.0 
OMM                            
Left mandible 
T3 N1 M0 
39.7                           
5.4 
4 x 8 
0.1                             
0.5 
PR 
Acute: 1                                  
Late: 1  
Acute: 0                              
Subacute: 0                   
Late: 0 
178 
Metronomic 
chemo 
Temozolomide 
(2 cycles) 
360 
6 
Domestic short-haired             
cat  
15.5 4.9 
VAS                           
Right abdominal 
wall 
T1 N0 M1 
13.0                          
3.9 
5 x 6 
1.0                            
2.0 
PR 
Acute: 1                         
Late: n.a.  
Acute: 0                              
Subacute: n.a.                
Late: n.a. 
76
Metronomic 
chemo 
76 
7 Labrador Retriever 11.3 36.6 
PVWT                      
Right popliteal 
T2a N0 M0 
912.4                        
20.5 
5 x 6 
623.1                       
17.0 
SD 
Acute: 2                    
Late: 1  
Acute: 0                             
Subacute: 0                 
Late: 0 
38 Debulking 302* 
8 
Domestic short-haired             
cat  
12.4 5.5 
VAS                                
Right scapula 
T2b N0 M0 
230.4                           
11.0 
5 x 6 
164.9                       
10.5 
SD 
Acute: 1                                            
Late: n.a. 
Acute: 0                     
Subacute: n.a.                 
Late: n.a. 
50  62 
PVWT, perivascular wall tumor; HSA, hemangiosarcoma; VAS, vaccine-associated sarcoma; OMM, oral malignant melanoma; TV, tumor volume; LD, longest diameter measured by caliper; Best response, maximum reduction in LD; PR, 
partial remission; SD, stable disease; RT, radiation therapy; HT, hyperthermia; n.a., not assessable; PFI, Progression free interval; OS, Overall survival; *, censored, still alive                                                                                                                                        
a Characterization of response according to RECIST (v1.0) 
b Radiation toxicity criteria according to VRTOG 
c Classification of hyperthermia-specific side effects according to CTCAE v4.03 and QMHT 
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Table 2. Hyperthermia treatment parameters of all eight animals                       
Animal 
Treatment planning   Intra-tumoral temperatures during hyperthermia 
Histogram in tumor         Transponder A   Transponder B   Transponder C 
T90 from 
histogram  
T10 from 
histogram  
    
Number of 
applicators 
Initial power 
Bolus 
temperature            
  Minimum Maximum   Minimum Maximum   Minimum Maximum 
[°C] [°C] [°C]   [W] [°C]   [°C] [°C]   [°C] [°C]   [°C] [°C] 
1 40.4 44.2 3.8 1 5.0 40 
  39.4 44.8   42.0 44.8       
  39.2 41.2   40.6 43.2       
  40.0 42.0   40.1 43.1       
2 38.4 42.6 4.2 1 5.5 38 
  39.1 43.4   42.0 43.3   40.3 42.0 
  40.0 41.5   39.6 45.0   40.2 42.5 
  39.1 41.4   41.9 43.3   40.3 41.2 
3 38.9 42.4 3.5 1 2.0 41 
  41.7 42.6   
Lost 
      
  41.2 42.4         
  41.3 41.8         
4 40.4 43.0 2.6 1 4.0 40 
  Not readable   40.8 42.6   41.8 42.8 
  42.9 44.2   41.6 43.2   42.2 43.2 
  41.0 43.8   39.2 40.8*   39.5 43.2 
5 38.4 43.8 5.4 1 5.0 40 
  38.8 43.6   40.1 43.0       
  41.3 44.8   40.6 45.3       
  42.0 43.4   39.4 41.9       
6 40.3 43.6 3.3 1 5.5 41 
  42.2 45.7   42.3 44.1       
  Not readable   39.0 42.8       
  42.0 44.2   41.7 44.2       
7 37.7 43.4 5.7 3 5.5 each 30 
  39.5 40.3*   Not readable   39.4 40.2* 
  Not readable   Not readable   39.2 40.2* 
  Not readable   41.2 42.3   39.6 40.9* 
8 38.0 43.4 5.4 2 4.5 each 40 
  40.8 41.8   Not readable   41.6 42.5 
  41.0 42.3   Not readable   41.4 43.2 
  41.7 43.6   Not readable   41.5 42.8 
T90, minimum temperature reached by 90% of the tumor volume; T10, minimum temperature reached by 10% of the tumor volume; ΔT=T10-T90; Lost, transponder not available during treatment; Not readable, limited 
readability of the transponder during treatment; *, aimed temperature of ≥41°C not reached   
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